علاج التنكس المخيخي المرافق للأورام في متلازمة المخيخ سريعة التطور مع الأجسام المضادة للخلايا العصبية ضد المستضدات داخل الخلوية

References

DOI: 10.3390/brainsci11111414

• If a specific antibody has been detected, one can distinguish between antibodies directed against intracellular antigens and antibodies directed against cell-surface antigens.
• In the first case, regimens targeting T-cell based mechanisms might be of advantage.
• If a patient presents with a typical clinical syndrome and specific antineuronal antibodies are detected or suspected, acute therapeutical settings aim to reduce brain inflammation and levels of circulating antibodies.
• In most cases, treatment of the underlying oncological disorder is paramount for the treatment of the paraneoplastic syndrome as well.
• Of course, choice of oncological treatment options (surgery, chemotherapy, radiotherapy) depends on tumor entity, staging, and individual aspects.